Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ester Oneda

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Endocrine-Related Cancer|April 23, 2017
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancerElisa Roca, Alfredo Berruti, Silviu Sbiera, et al.
Targeted Oncology|September 17, 2022
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory AnalysisMargherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, et al.
Therapeutic Advances in Medical Oncology|July 17, 2023
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experienceMargherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 25, 2024
Tackling challenges in rare diseases: The ISGACA approach on non-pancreatic cancers in the periampullary regionBas A Uijterwijk, Daniël H Lemmers, Alma L Moekotte, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Endocrine-Related Cancer|April 23, 2017
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancerElisa Roca, Alfredo Berruti, Silviu Sbiera, et al.
Targeted Oncology|September 17, 2022
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory AnalysisMargherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, et al.
Therapeutic Advances in Medical Oncology|July 17, 2023
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experienceMargherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 25, 2024
Tackling challenges in rare diseases: The ISGACA approach on non-pancreatic cancers in the periampullary regionBas A Uijterwijk, Daniël H Lemmers, Alma L Moekotte, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.
Pageof 4